QCG
SPRY icon

Quadrant Capital Group’s ARS Pharmaceuticals SPRY Stock Holding History

Quadrant Capital Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-347
Closed -$2.79K – 2397
2026
Q1 		$2.79K Hold
347
– – ﹤0.01% 2464
2025
Q4 		$4.04K Hold
347
– – ﹤0.01% 2414
2025
Q3 		$3.49K Buy
+347
New +$4.98K ﹤0.01% 2388
2025
Q2 		– Sell
-347
Closed -$4.37K – 2450
2025
Q1 		$4.37K Hold
347
– – ﹤0.01% 2380
2024
Q4 		$3.66K Hold
347
– – ﹤0.01% 2379
2024
Q3 		$5.03K Hold
347
– – ﹤0.01% 2318
2024
Q2 		$2.95K Hold
347
– – ﹤0.01% 2415
2024
Q1 		$3.55K Hold
347
– – ﹤0.01% 2397
2023
Q4 		$1.9K Buy
+347
New +$1.52K ﹤0.01% 2483

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Quadrant Capital Group's SPRY Position: Q2 2026 in Review

Quadrant Capital Group sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 347 shares — an estimated $2.79K sold.

Quadrant Capital Group first reported a position in SPRY in Q4 2023 and held it in 9 quarters. The position peaked at $5.03K in Q3 2024. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Quadrant Capital Group reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 347 ARS Pharmaceuticals shares in Q2 2026, an estimated $2.79K.
  • Quadrant Capital Group first reported a position in ARS Pharmaceuticals in Q4 2023 and held it in 9 quarters.
  • Quadrant Capital Group's ARS Pharmaceuticals position peaked at $5.03K in Q3 2024.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.